Keryx Biopharmaceuticals, Inc. (KERX) Downgraded by ValuEngine


Several other research firms have also commented on KERX. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a hold rating to a buy rating and set a $8.75 price objective for the company in a research note on Wednesday, July 12th.



from Biotech News